POPULARITY
5 episodes with amy goodrich
4 episodes with amy goodrich
4 episodes with amy goodrich
4 episodes with amy goodrich
3 episodes with amy goodrich
3 episodes with amy goodrich
2 episodes with amy goodrich
4 episodes with amy goodrich
2 episodes with amy goodrich
Featuring an interview with Ms Amy Goodrich, including the following topics: Presentation and management of follicular lymphoma (FL) (0:00) Case: A woman in her late 70s with heavily pretreated disease experiences complete response to mosunetuzumab (24:41) Case: A man in his early 60s with extensive diffuse large B-cell lymphoma and short response to CAR-T is successfully bridged to allogeneic transplant with glofitamab (30:15) Case: A man in his late 50s with transformed FL has limited treatment options due to lack of social support (45:51) Effects of bispecific antibodies in follicular and diffuse large B-cell lymphoma (52:53) NCPD information and select publications
Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. NCPD information and select publications here.
Featuring perspectives from Dr Christopher R Flowers, Ms Amy Goodrich, Ms Robin Klebig and Dr Matthew Lunning, including the following topics: Introduction (0:00) POLARIX: Polatuzumab Vedotin/R-CHP for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (5:55) Polatuzumab Vedotin/Bendamustine/Rituximab and Selinexor for Relapsed Disease (24:28) CD19-Directed Antibody-Drug Conjugate Loncastuximab Tesirine (42:43) CD19-Directed Monoclonal Antibody Tafasitamab Combined with Lenalidomide (51:16) CD20 x CD3 Bispecific Antibodies (1:01:02) CAR (Chimeric Antigen Receptor) T-Cell Therapy (1:19:07) NCPD information and select publications
Treatment for patients with CLL has undergone a dramatic transformation with the approval of oral oncolytics. Oral oncolytic treatment for CLL offers many benefits such as convenience and effectiveness. However, with the introduction of oral oncolytic treatments, cancer care teams face new challenges (e.g., medication adherence, prescription interactions, toxicity management, financial burdens, among others). CANCER BUZZ spoke to Amy Goodrich, CRNP, Nurse Practitioner at John Hopkins Kimmel Cancer Center in Baltimore, MD. Hear about a nurse's role in care planning, engaging patients in education, and shared decision making for treatment goals and planning. “We've been short oncologists for a long time, nurse practitioners and other advanced practitioners fill that gap… But our oncology nurses are such an important part of the care of these patients with just being the day-to-day touchpoints for these folks and really knowing how to engage with patients and really flesh out what is going on with them...” – Amy Goodrich, CRNP Amy Goodrich, CRNP Nurse Practitioner Johns Hopkins Kimmel Cancer Center Baltimore, MD Resources: Blog: Integrating Oral Oncolytics into Chronic Lymphocytic Leukemia Practice Integrating Oral Oncolytics into Chronic Lymphocytic Leukemia (CLL) Practice Successful Integration of Oral Oncolytics-Podcast EP 96 The Role of Pharmacy to Help Manage Patients with Cancer on Oral Oncolytics
In this episode, Tycel J. Phillips, MD, and Amy Goodrich, RN, MSN, CRNP-AC, provide expert insights on key data presented at ASCO 2022 for mantle cell lymphoma regarding:Results from the phase III SHINE study of the addition of ibrutinib the first-line BR followed by rituximab maintenance in older patients with MCLUpdated results from the phase II ZUMA-2 study evaluating brexucabtagene autoleucel for patients with R/R MCLResults from a phase I/II study of the ROR1 humanized monoclonal antibody, zilovertamab, in combination with ibrutinib for patients with R/R MCL, MZL, or CLL/SLLPreliminary results from a phase I study of the humanized ROR1xCD3 bispecific antibody, NVG-111, in R/R CLL and MCL after ≥2 previous therapiesPresenters:Tycel J. Phillips, MD Maria Reinhardt Decesare Research Professor of Blood Cancers and Bone Marrow TransplantationAssociate Professor of MedicineUniversity of Michigan Rogel Cancer Center Ann Arbor, MichiganAmy Goodrich, RN, MSN, CRNP-ACResearch Associate, Department of MedicineJohns Hopkins UniversityNurse Practitioner, Department of MedicineThe Sidney Kimmel Comprehensive Cancer CenterBaltimore, MarylandContent supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.Link to full program, including a downloadable highlights slideset:https://bit.ly/3yufCU4
Featuring perspectives from Ms Lesley Camille Ballance, Ms Amy Goodrich, Dr Lowell Hart and Dr Anthony Mato, including the following topics: Introduction (0:00) Overview of Chronic Lymphocytic Leukemia (5:47) Bruton Tyrosine Kinase Inhibitors (27:40) Venetoclax and Anti-CD20 Antibody Therapy (58:59) Future Strategies (1:15:51) NCPD information and select publications
Go online to PeerView.com/QWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the current clinical challenges of CLL—including in areas where nurse professionals can have a decisive influence on patient education and the safe delivery of care? This “Clinical Consults” activity, developed in collaboration with the CLL Society, represents a resource for developing modern management strategies in a changing and complicated therapeutic landscape. Throughout, PeerView's expert speakers present nurse-to-nurse, case-based education and share clinical tools designed to facilitate the effective use of innovative therapeutics in chronic lymphocytic leukemia (CLL) across multiple treatment settings, with the ultimate goal of enhancing patient outcomes. Upon completion of this activity, participants should be better able to: Cite the clinical signs of symptomatic disease, relevant prognostic factors, patient- and disease-related features, and clinical evidence that can inform treatment selection with innovative therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cellular therapy, Provide counseling to patients with CLL in order to clarify therapeutic expectations, safety considerations, appropriate dosing, sequential therapy, and differences among novel agent classes, Address dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Go online to PeerView.com/QWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the current clinical challenges of CLL—including in areas where nurse professionals can have a decisive influence on patient education and the safe delivery of care? This “Clinical Consults” activity, developed in collaboration with the CLL Society, represents a resource for developing modern management strategies in a changing and complicated therapeutic landscape. Throughout, PeerView's expert speakers present nurse-to-nurse, case-based education and share clinical tools designed to facilitate the effective use of innovative therapeutics in chronic lymphocytic leukemia (CLL) across multiple treatment settings, with the ultimate goal of enhancing patient outcomes. Upon completion of this activity, participants should be better able to: Cite the clinical signs of symptomatic disease, relevant prognostic factors, patient- and disease-related features, and clinical evidence that can inform treatment selection with innovative therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cellular therapy, Provide counseling to patients with CLL in order to clarify therapeutic expectations, safety considerations, appropriate dosing, sequential therapy, and differences among novel agent classes, Address dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Go online to PeerView.com/QWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the current clinical challenges of CLL—including in areas where nurse professionals can have a decisive influence on patient education and the safe delivery of care? This “Clinical Consults” activity, developed in collaboration with the CLL Society, represents a resource for developing modern management strategies in a changing and complicated therapeutic landscape. Throughout, PeerView's expert speakers present nurse-to-nurse, case-based education and share clinical tools designed to facilitate the effective use of innovative therapeutics in chronic lymphocytic leukemia (CLL) across multiple treatment settings, with the ultimate goal of enhancing patient outcomes. Upon completion of this activity, participants should be better able to: Cite the clinical signs of symptomatic disease, relevant prognostic factors, patient- and disease-related features, and clinical evidence that can inform treatment selection with innovative therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cellular therapy, Provide counseling to patients with CLL in order to clarify therapeutic expectations, safety considerations, appropriate dosing, sequential therapy, and differences among novel agent classes, Address dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Go online to PeerView.com/QWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the current clinical challenges of CLL—including in areas where nurse professionals can have a decisive influence on patient education and the safe delivery of care? This “Clinical Consults” activity, developed in collaboration with the CLL Society, represents a resource for developing modern management strategies in a changing and complicated therapeutic landscape. Throughout, PeerView's expert speakers present nurse-to-nurse, case-based education and share clinical tools designed to facilitate the effective use of innovative therapeutics in chronic lymphocytic leukemia (CLL) across multiple treatment settings, with the ultimate goal of enhancing patient outcomes. Upon completion of this activity, participants should be better able to: Cite the clinical signs of symptomatic disease, relevant prognostic factors, patient- and disease-related features, and clinical evidence that can inform treatment selection with innovative therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cellular therapy, Provide counseling to patients with CLL in order to clarify therapeutic expectations, safety considerations, appropriate dosing, sequential therapy, and differences among novel agent classes, Address dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Go online to PeerView.com/QWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the current clinical challenges of CLL—including in areas where nurse professionals can have a decisive influence on patient education and the safe delivery of care? This “Clinical Consults” activity, developed in collaboration with the CLL Society, represents a resource for developing modern management strategies in a changing and complicated therapeutic landscape. Throughout, PeerView's expert speakers present nurse-to-nurse, case-based education and share clinical tools designed to facilitate the effective use of innovative therapeutics in chronic lymphocytic leukemia (CLL) across multiple treatment settings, with the ultimate goal of enhancing patient outcomes. Upon completion of this activity, participants should be better able to: Cite the clinical signs of symptomatic disease, relevant prognostic factors, patient- and disease-related features, and clinical evidence that can inform treatment selection with innovative therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cellular therapy, Provide counseling to patients with CLL in order to clarify therapeutic expectations, safety considerations, appropriate dosing, sequential therapy, and differences among novel agent classes, Address dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Go online to PeerView.com/QWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for the current clinical challenges of CLL—including in areas where nurse professionals can have a decisive influence on patient education and the safe delivery of care? This “Clinical Consults” activity, developed in collaboration with the CLL Society, represents a resource for developing modern management strategies in a changing and complicated therapeutic landscape. Throughout, PeerView's expert speakers present nurse-to-nurse, case-based education and share clinical tools designed to facilitate the effective use of innovative therapeutics in chronic lymphocytic leukemia (CLL) across multiple treatment settings, with the ultimate goal of enhancing patient outcomes. Upon completion of this activity, participants should be better able to: Cite the clinical signs of symptomatic disease, relevant prognostic factors, patient- and disease-related features, and clinical evidence that can inform treatment selection with innovative therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cellular therapy, Provide counseling to patients with CLL in order to clarify therapeutic expectations, safety considerations, appropriate dosing, sequential therapy, and differences among novel agent classes, Address dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other innovative approaches to treatment.
Jeff Regan Investigator starring Frank Graham, originally broadcast October 26, 1949, 72 years ago, The Lady who wanted to live. Amy Goodrich needs protection from Tim Conover, the owner of the Diamond Club.
A special audio program developed from a series of 6 fall webinars held following the 2021 ONS Annual Congress. Featuring perspectives from Dr John Leonard and Ms Amy Goodrich moderated by Dr Neil Love.
Featuring perspectives from Dr John Leonard and Ms Amy Goodrich, including the following topics: Introduction (0:00) Diffuse Large B-Cell Lymphoma (1:24) Case: A man in his late 20s with newly diagnosed Hodgkin lymphoma — Amy Goodrich, CRNP (23:50) Hodgkin Lymphoma (27:04) Follicular Lymphoma (37:25) Case: A woman in her early 50s with Stage IVB follicular lymphoma — Ms Goodrich (45:25) Mantle Cell Lymphoma (50:52) Case: A man in his late 50s with Stage IVB mantle cell lymphoma — Ms Goodrich (53:53) NCPD information and select publications
Featuring a roundtable discussion with Ms Amy Goodrich and Drs Gigi Chen, Ilya Glezerman, Dipti Gupta, Yanjun Ma and Anthony R Mato, moderated by Dr Neil Love.
Featuring a roundtable discussion with Ms Amy Goodrich and Drs Gigi Chen, Ilya Glezerman, Dipti Gupta, Yanjun Ma and Anthony R Mato, including the following topics: Case: A man in his mid-50s with treatment-naïve chronic lymphocytic leukemia (CLL) with no IGHV mutation begins therapy with venetoclax/obinutuzumab and develops tumor lysis syndrome (TLS) after cycle 1 of obinutuzumab — Anthony R Mato, MD, MSCE (0:00) Assessing patients with CLL for risk of TLS; use of antihyperuricemic agents (rasburicase and allopurinol) in the management of TLS associated with venetoclax/obinutuzumab (7:21) Selection of first-line therapy for patients with CLL (16:33) Perspective on the choice of Bruton tyrosine kinase (BTK) inhibitors versus venetoclax/obinutuzumab as up-front therapy (21:10) Results of the Phase III ELEVATE-RR study evaluating acalabrutinib versus ibrutinib for patients with previously treated, high-risk CLL; key findings from the ALPINE study comparing zanubrutinib to ibrutinib for relapsed CLL (24:01) GLOW: A Phase III trial of ibrutinib and venetoclax for untreated CLL/small lymphocytic lymphoma; efficacy and tolerability of LOXO-305 (pirtobrutinib) for CLL (29:44) Case: A man in his mid-40s with treatment-naïve CLL with an IGHV mutation receives venetoclax/obinutuzumab and develops neutropenia — Dr Mato (34:08) Treatment of neutropenia associated with venetoclax/obinutuzumab (38:11) Monitoring and management of renal dysfunction related to venetoclax-based regimens (44:23) Case: A man in his mid-60s with relapsed/refractory CLL who experiences disease progression on ibrutinib starts therapy with venetoclax/rituximab and develops biochemical TLS — Dr Mato (48:44) Pathophysiology of TLS; laboratory and clinical criteria for identifying patients at risk (51:30) Recommendations for mitigating the risk associated with TLS; real-world data on risk and prophylaxis (1:00:42) Efficacy and tolerability of febuxostat, allopurinol or rasburicase for the prevention and management of TLS (1:05:13) Case: A woman in her late 80s with relapsed/refractory CLL and underlying renal disease receives venetoclax monotherapy — Dr Mato (1:10:07) Case: A man in his early 60s with CLL develops atrial fibrillation after first-line therapy with ibrutinib — Dr Mato (1:23:30) Management of atrial fibrillation associated with ibrutinib (1:25:13) Evaluation of patients with atrial fibrillation; perspective on switching BTK inhibitors for those who develop cardiac adverse events (1:33:29) Cardiac side effects of BTK inhibitors; hypertension and ventricular arrythmias associated with ibrutinib (1:37:57) Incidence, risk factors and treatment of atrial fibrillation and bleeding related to ibrutinib (1:44:28) CME information and select publications
In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing serious adverse events associated with BTK inhibitor therapy. Topics in this podcast include:Atrial fibrillationCardiac toxicityMusculoskeletal AEsManaging risk of infectionsPresenter: Amy Goodrich, RN, MSN, CRNP-AC Research Associate/Nurse PractitionerSidney Kimmel Comprehensive Cancer CenterJohns Hopkins UniversityBaltimore, MarylandCE/AAPA credit available by visiting the online program:https://bit.ly/3zMXFOpLink to full program, including downloadable slidesets:https://bit.ly/3iwN9Ub
In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics in this podcast include:BTK inhibitor selectivityBTK inhibitor adverse event profilesIbrutinib intoleranceManagement of common adverse eventsPresenter:Amy Goodrich, RN, MSN, CRNP-ACResearch Associate/Nurse PractitionerSidney Kimmel Comprehensive Cancer CenterJohns Hopkins UniversityBaltimore, MarylandLink to full program, including downloadable slidesets:https://bit.ly/3iwN9Ub
Go online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of and efficacy expectations with novel antibodies for DLBCL; understanding safety considerations, such as infusion reactions, myelosuppression, and infections associated with antibody-based options; and counseling patients on appropriate dosing, treatment schedules, and clinical trials for R/R DLBCL. Upon completion of this accredited CE activity, participants should be better able to: Cite the current therapeutic role of novel antibody therapy, including CD19-, CD30-, CD79-, and CD20-directed agents, in relapsed diffuse large B-cell lymphoma (DLBCL), Discuss efficacy and safety evidence surrounding the use of antibody regimens in patients with DLBCL, Develop an education plan for patients with DLBCL focused on the efficacy and safety profiles of novel antibody-based treatments, Manage the unique spectrum of antibody-associated adverse events and dosing/administration considerations in the DLBCL setting.
Go online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of and efficacy expectations with novel antibodies for DLBCL; understanding safety considerations, such as infusion reactions, myelosuppression, and infections associated with antibody-based options; and counseling patients on appropriate dosing, treatment schedules, and clinical trials for R/R DLBCL. Upon completion of this accredited CE activity, participants should be better able to: Cite the current therapeutic role of novel antibody therapy, including CD19-, CD30-, CD79-, and CD20-directed agents, in relapsed diffuse large B-cell lymphoma (DLBCL), Discuss efficacy and safety evidence surrounding the use of antibody regimens in patients with DLBCL, Develop an education plan for patients with DLBCL focused on the efficacy and safety profiles of novel antibody-based treatments, Manage the unique spectrum of antibody-associated adverse events and dosing/administration considerations in the DLBCL setting.
Go online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of and efficacy expectations with novel antibodies for DLBCL; understanding safety considerations, such as infusion reactions, myelosuppression, and infections associated with antibody-based options; and counseling patients on appropriate dosing, treatment schedules, and clinical trials for R/R DLBCL. Upon completion of this accredited CE activity, participants should be better able to: Cite the current therapeutic role of novel antibody therapy, including CD19-, CD30-, CD79-, and CD20-directed agents, in relapsed diffuse large B-cell lymphoma (DLBCL), Discuss efficacy and safety evidence surrounding the use of antibody regimens in patients with DLBCL, Develop an education plan for patients with DLBCL focused on the efficacy and safety profiles of novel antibody-based treatments, Manage the unique spectrum of antibody-associated adverse events and dosing/administration considerations in the DLBCL setting.
Go online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of and efficacy expectations with novel antibodies for DLBCL; understanding safety considerations, such as infusion reactions, myelosuppression, and infections associated with antibody-based options; and counseling patients on appropriate dosing, treatment schedules, and clinical trials for R/R DLBCL. Upon completion of this accredited CE activity, participants should be better able to: Cite the current therapeutic role of novel antibody therapy, including CD19-, CD30-, CD79-, and CD20-directed agents, in relapsed diffuse large B-cell lymphoma (DLBCL), Discuss efficacy and safety evidence surrounding the use of antibody regimens in patients with DLBCL, Develop an education plan for patients with DLBCL focused on the efficacy and safety profiles of novel antibody-based treatments, Manage the unique spectrum of antibody-associated adverse events and dosing/administration considerations in the DLBCL setting.
Go online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of and efficacy expectations with novel antibodies for DLBCL; understanding safety considerations, such as infusion reactions, myelosuppression, and infections associated with antibody-based options; and counseling patients on appropriate dosing, treatment schedules, and clinical trials for R/R DLBCL. Upon completion of this accredited CE activity, participants should be better able to: Cite the current therapeutic role of novel antibody therapy, including CD19-, CD30-, CD79-, and CD20-directed agents, in relapsed diffuse large B-cell lymphoma (DLBCL), Discuss efficacy and safety evidence surrounding the use of antibody regimens in patients with DLBCL, Develop an education plan for patients with DLBCL focused on the efficacy and safety profiles of novel antibody-based treatments, Manage the unique spectrum of antibody-associated adverse events and dosing/administration considerations in the DLBCL setting.
Go online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of and efficacy expectations with novel antibodies for DLBCL; understanding safety considerations, such as infusion reactions, myelosuppression, and infections associated with antibody-based options; and counseling patients on appropriate dosing, treatment schedules, and clinical trials for R/R DLBCL. Upon completion of this accredited CE activity, participants should be better able to: Cite the current therapeutic role of novel antibody therapy, including CD19-, CD30-, CD79-, and CD20-directed agents, in relapsed diffuse large B-cell lymphoma (DLBCL), Discuss efficacy and safety evidence surrounding the use of antibody regimens in patients with DLBCL, Develop an education plan for patients with DLBCL focused on the efficacy and safety profiles of novel antibody-based treatments, Manage the unique spectrum of antibody-associated adverse events and dosing/administration considerations in the DLBCL setting.
Go online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of and efficacy expectations with novel antibodies for DLBCL; understanding safety considerations, such as infusion reactions, myelosuppression, and infections associated with antibody-based options; and counseling patients on appropriate dosing, treatment schedules, and clinical trials for R/R DLBCL. Upon completion of this accredited CE activity, participants should be better able to: Cite the current therapeutic role of novel antibody therapy, including CD19-, CD30-, CD79-, and CD20-directed agents, in relapsed diffuse large B-cell lymphoma (DLBCL), Discuss efficacy and safety evidence surrounding the use of antibody regimens in patients with DLBCL, Develop an education plan for patients with DLBCL focused on the efficacy and safety profiles of novel antibody-based treatments, Manage the unique spectrum of antibody-associated adverse events and dosing/administration considerations in the DLBCL setting.
Go online to PeerView.com/DFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This NCPD/ILNA-certified “Nurse Clinical Consults” webcast on antibody-based treatment options for patients with DLBCL, originally a live broadcast during the 2021 ONS Congress, features Lesley Camille Ballance, MSN, FNP-BC, Amy Goodrich, CRNP, and Jill Lozensky, RN, BSN, OCN. Hear what these experts have to say about educating patients on the clinical role of and efficacy expectations with novel antibodies for DLBCL; understanding safety considerations, such as infusion reactions, myelosuppression, and infections associated with antibody-based options; and counseling patients on appropriate dosing, treatment schedules, and clinical trials for R/R DLBCL. Upon completion of this accredited CE activity, participants should be better able to: Cite the current therapeutic role of novel antibody therapy, including CD19-, CD30-, CD79-, and CD20-directed agents, in relapsed diffuse large B-cell lymphoma (DLBCL), Discuss efficacy and safety evidence surrounding the use of antibody regimens in patients with DLBCL, Develop an education plan for patients with DLBCL focused on the efficacy and safety profiles of novel antibody-based treatments, Manage the unique spectrum of antibody-associated adverse events and dosing/administration considerations in the DLBCL setting.
Go online to PeerView.com/GKP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS Congress, Amy Goodrich, CRNP, Josie Montegaard, MSN, AGNP-BC, and Lisa Nodzon, PhD, ARNP, AOCNP, discuss practical applications of the latest evidence on targeted therapeutics to nursing care in CLL, as they present a rich collection of clinical examples from nursing practice. A patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey is also featured. Upon completion of this accredited CE activity, participants should be better able to: Cite the clinical signs, relevant prognostic factors, and patient- or disease-related features that influence treatment selection for CLL, Summarize updated clinical efficacy and safety evidence surrounding novel therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cell therapy, Develop educational strategies for patients with CLL related to therapeutic expectations, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other approaches to treatment.
Go online to PeerView.com/GKP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS Congress, Amy Goodrich, CRNP, Josie Montegaard, MSN, AGNP-BC, and Lisa Nodzon, PhD, ARNP, AOCNP, discuss practical applications of the latest evidence on targeted therapeutics to nursing care in CLL, as they present a rich collection of clinical examples from nursing practice. A patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey is also featured. Upon completion of this accredited CE activity, participants should be better able to: Cite the clinical signs, relevant prognostic factors, and patient- or disease-related features that influence treatment selection for CLL, Summarize updated clinical efficacy and safety evidence surrounding novel therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cell therapy, Develop educational strategies for patients with CLL related to therapeutic expectations, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other approaches to treatment.
Go online to PeerView.com/GKP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS Congress, Amy Goodrich, CRNP, Josie Montegaard, MSN, AGNP-BC, and Lisa Nodzon, PhD, ARNP, AOCNP, discuss practical applications of the latest evidence on targeted therapeutics to nursing care in CLL, as they present a rich collection of clinical examples from nursing practice. A patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey is also featured. Upon completion of this accredited CE activity, participants should be better able to: Cite the clinical signs, relevant prognostic factors, and patient- or disease-related features that influence treatment selection for CLL, Summarize updated clinical efficacy and safety evidence surrounding novel therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cell therapy, Develop educational strategies for patients with CLL related to therapeutic expectations, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other approaches to treatment.
Go online to PeerView.com/GKP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS Congress, Amy Goodrich, CRNP, Josie Montegaard, MSN, AGNP-BC, and Lisa Nodzon, PhD, ARNP, AOCNP, discuss practical applications of the latest evidence on targeted therapeutics to nursing care in CLL, as they present a rich collection of clinical examples from nursing practice. A patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey is also featured. Upon completion of this accredited CE activity, participants should be better able to: Cite the clinical signs, relevant prognostic factors, and patient- or disease-related features that influence treatment selection for CLL, Summarize updated clinical efficacy and safety evidence surrounding novel therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cell therapy, Develop educational strategies for patients with CLL related to therapeutic expectations, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other approaches to treatment.
Go online to PeerView.com/GKP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS Congress, Amy Goodrich, CRNP, Josie Montegaard, MSN, AGNP-BC, and Lisa Nodzon, PhD, ARNP, AOCNP, discuss practical applications of the latest evidence on targeted therapeutics to nursing care in CLL, as they present a rich collection of clinical examples from nursing practice. A patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey is also featured. Upon completion of this accredited CE activity, participants should be better able to: Cite the clinical signs, relevant prognostic factors, and patient- or disease-related features that influence treatment selection for CLL, Summarize updated clinical efficacy and safety evidence surrounding novel therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cell therapy, Develop educational strategies for patients with CLL related to therapeutic expectations, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other approaches to treatment.
Go online to PeerView.com/GKP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS Congress, Amy Goodrich, CRNP, Josie Montegaard, MSN, AGNP-BC, and Lisa Nodzon, PhD, ARNP, AOCNP, discuss practical applications of the latest evidence on targeted therapeutics to nursing care in CLL, as they present a rich collection of clinical examples from nursing practice. A patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey is also featured. Upon completion of this accredited CE activity, participants should be better able to: Cite the clinical signs, relevant prognostic factors, and patient- or disease-related features that influence treatment selection for CLL, Summarize updated clinical efficacy and safety evidence surrounding novel therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cell therapy, Develop educational strategies for patients with CLL related to therapeutic expectations, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other approaches to treatment.
Go online to PeerView.com/GKP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS Congress, Amy Goodrich, CRNP, Josie Montegaard, MSN, AGNP-BC, and Lisa Nodzon, PhD, ARNP, AOCNP, discuss practical applications of the latest evidence on targeted therapeutics to nursing care in CLL, as they present a rich collection of clinical examples from nursing practice. A patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey is also featured. Upon completion of this accredited CE activity, participants should be better able to: Cite the clinical signs, relevant prognostic factors, and patient- or disease-related features that influence treatment selection for CLL, Summarize updated clinical efficacy and safety evidence surrounding novel therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cell therapy, Develop educational strategies for patients with CLL related to therapeutic expectations, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other approaches to treatment.
Go online to PeerView.com/GKP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this replay of a webcast during the 2021 ONS Congress, Amy Goodrich, CRNP, Josie Montegaard, MSN, AGNP-BC, and Lisa Nodzon, PhD, ARNP, AOCNP, discuss practical applications of the latest evidence on targeted therapeutics to nursing care in CLL, as they present a rich collection of clinical examples from nursing practice. A patient video testimonial on the nurse–patient relationship and the key role of nurses as patient educators during the therapeutic journey is also featured. Upon completion of this accredited CE activity, participants should be better able to: Cite the clinical signs, relevant prognostic factors, and patient- or disease-related features that influence treatment selection for CLL, Summarize updated clinical efficacy and safety evidence surrounding novel therapeutic classes in CLL, including BTK and BCL-2 inhibitors, novel antibodies, and cell therapy, Develop educational strategies for patients with CLL related to therapeutic expectations, safety considerations, sequential treatments, and differences among novel agent classes, Manage dosing and safety considerations for patients with CLL receiving BTK or BCL-2 inhibitors, novel antibodies, or other approaches to treatment.
Video proceedings from the second in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Christopher R Flowers, Ms Amy Goodrich, Dr Patrick B Johnston and Ms Robin Klebig: Introduction (00:00) Program overview: Dr Love Hodgkin Lymphoma (HL) (2:51) Case (Ms Klebig): A woman in her early 50s with HL who received up-front brentuximab vedotin with ABVD on a clinical trial and nivolumab after relapse (5:57) Case (Ms Goodrich): A man in his mid-50s with relapsed HL who received brentuximab vedotin as a bridge to allogenic transplant (26:12) Follicular Lymphoma (FL) (37:16) Case (Ms Klebig): A man in his late 50s with multiply relapsed FL who received lenalidomide/rituximab with response and clinical improvement (38:46) Case (Ms Goodrich): A man in his late 40s with relapsed FL who received copanlisib (1:07:01) Mantle Cell Lymphoma (MCL) (1:09:53) Case (Ms Goodrich): A man in his early 80s with relapsed MCL and multiple comorbidities who received acalabrutinib (1:19:36) Case (Ms Goodrich): A man in his early 60s who received multiple lines of therapy for relapsed MCL, including venetoclax/rituximab (1:27:21) Diffuse Large B-Cell Lymphoma (DLBCL) (1:34:06) Case (MS Klebig): A woman in her mid-30s with relapsed triple-hit DLBCL who underwent chimeric antigen receptor T-cell therapy (1:34:12) Case (Ms Klebig): A woman in her mid-30s with DLBCL who received CNS prophylaxis with high-dose methotrexate (1:37:16) Select publications
Go online to PeerView.com/JHB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology-oncology nurse expert reviews the latest evidence on novel agent classes and ongoing research in B-cell lymphoma and offers insights on practical issues that nurses caring for patients with B-cell malignancies face in routine practice. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data associated with novel agent classes and other emerging therapies in B-cell lymphoma, including BTK, PI3K, and BCL-2 inhibitors, immunomodulators, antibodies, and CAR-T cell therapy, among others, Cite dosage, administration strategies, and treatment schedules of novel agent classes for the management of newly diagnosed or refractory/relapsed B-cell lymphoma, Apply successful patient educational strategies related to novel therapies and ongoing clinical trials to increase compliance with and adherence to novel regimens for B-cell lymphoma, Utilize effective side effect prevention and management strategies related to novel therapies in patients with B-cell malignancies.
Go online to PeerView.com/JHB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology-oncology nurse expert reviews the latest evidence on novel agent classes and ongoing research in B-cell lymphoma and offers insights on practical issues that nurses caring for patients with B-cell malignancies face in routine practice. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data associated with novel agent classes and other emerging therapies in B-cell lymphoma, including BTK, PI3K, and BCL-2 inhibitors, immunomodulators, antibodies, and CAR-T cell therapy, among others, Cite dosage, administration strategies, and treatment schedules of novel agent classes for the management of newly diagnosed or refractory/relapsed B-cell lymphoma, Apply successful patient educational strategies related to novel therapies and ongoing clinical trials to increase compliance with and adherence to novel regimens for B-cell lymphoma, Utilize effective side effect prevention and management strategies related to novel therapies in patients with B-cell malignancies.
Go online to PeerView.com/JHB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology-oncology nurse expert reviews the latest evidence on novel agent classes and ongoing research in B-cell lymphoma and offers insights on practical issues that nurses caring for patients with B-cell malignancies face in routine practice. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data associated with novel agent classes and other emerging therapies in B-cell lymphoma, including BTK, PI3K, and BCL-2 inhibitors, immunomodulators, antibodies, and CAR-T cell therapy, among others, Cite dosage, administration strategies, and treatment schedules of novel agent classes for the management of newly diagnosed or refractory/relapsed B-cell lymphoma, Apply successful patient educational strategies related to novel therapies and ongoing clinical trials to increase compliance with and adherence to novel regimens for B-cell lymphoma, Utilize effective side effect prevention and management strategies related to novel therapies in patients with B-cell malignancies.
Go online to PeerView.com/JHB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology-oncology nurse expert reviews the latest evidence on novel agent classes and ongoing research in B-cell lymphoma and offers insights on practical issues that nurses caring for patients with B-cell malignancies face in routine practice. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data associated with novel agent classes and other emerging therapies in B-cell lymphoma, including BTK, PI3K, and BCL-2 inhibitors, immunomodulators, antibodies, and CAR-T cell therapy, among others, Cite dosage, administration strategies, and treatment schedules of novel agent classes for the management of newly diagnosed or refractory/relapsed B-cell lymphoma, Apply successful patient educational strategies related to novel therapies and ongoing clinical trials to increase compliance with and adherence to novel regimens for B-cell lymphoma, Utilize effective side effect prevention and management strategies related to novel therapies in patients with B-cell malignancies.
Go online to PeerView.com/JHB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology-oncology nurse expert reviews the latest evidence on novel agent classes and ongoing research in B-cell lymphoma and offers insights on practical issues that nurses caring for patients with B-cell malignancies face in routine practice. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data associated with novel agent classes and other emerging therapies in B-cell lymphoma, including BTK, PI3K, and BCL-2 inhibitors, immunomodulators, antibodies, and CAR-T cell therapy, among others, Cite dosage, administration strategies, and treatment schedules of novel agent classes for the management of newly diagnosed or refractory/relapsed B-cell lymphoma, Apply successful patient educational strategies related to novel therapies and ongoing clinical trials to increase compliance with and adherence to novel regimens for B-cell lymphoma, Utilize effective side effect prevention and management strategies related to novel therapies in patients with B-cell malignancies.
Go online to PeerView.com/JHB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology-oncology nurse expert reviews the latest evidence on novel agent classes and ongoing research in B-cell lymphoma and offers insights on practical issues that nurses caring for patients with B-cell malignancies face in routine practice. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data associated with novel agent classes and other emerging therapies in B-cell lymphoma, including BTK, PI3K, and BCL-2 inhibitors, immunomodulators, antibodies, and CAR-T cell therapy, among others, Cite dosage, administration strategies, and treatment schedules of novel agent classes for the management of newly diagnosed or refractory/relapsed B-cell lymphoma, Apply successful patient educational strategies related to novel therapies and ongoing clinical trials to increase compliance with and adherence to novel regimens for B-cell lymphoma, Utilize effective side effect prevention and management strategies related to novel therapies in patients with B-cell malignancies.
© 2020-2025 Ivy Podcast Discovery LLC
